LadRx Corp: M&A transaction — LadRx sells aldoxorubicin and arimoclomol royalty rights to XOMA for $5M upfront; up to $6M more

LadRx Corp

Gross proceeds $5M at closing; potential $6M milestones: $1M on FDA acceptance of arimoclomol NDA, $1M on first sale, $4M on aldoxorubicin FDA approval.
XOMA acquires all milestone and royalty payments from ImmunityBio and Zevra, net of existing obligations.
Proceeds to advance lead candidate LADR-7 toward IND filing; 12 months of final IND-enabling work estimated.
Transaction structured as non-dilutive financing; Roth Capital Partners acted as placement agent.

item 1.01 item 2.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

LadRx Corp completed a disposition involving XOMA (US) LLC for $5 million (closed 2023-06-21).

Action: disposition
Counterparty: XOMA (US) LLC
Consideration: $5 million
Closing: 2023-06-21

Exact text from the filing

purchase price paid to the Company for the sale, transfer, assignment and conveyance of the Company’s right, title and interest in and to aldoxorubicin and arimoclomol was $5 million, less certain transaction fees and expenses. As previously reported, on July 27, 2017, the Company entered into an exclusive worldwide license agreement (as amended, the “

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001493152-23-022337

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.